Nivolumab associated vasculopathy: A novel mechanism

Nivolumab associated vasculopathy: A novel mechanism

Bibliographic Details
Main Authors:	Adeeb Haroon, MS, James K. Parker, MD, Kara Braudis, MD, Emily H. Smith, MD
Format:	Article
Language:	English
Published:	Elsevier 2022-04-01
Series:	JAAD Case Reports
Subjects:	immune-related adverse event nivolumab vasculopathy
Online Access:	http://www.sciencedirect.com/science/article/pii/S235251262200056X

Similar Items

Eosinophilic Fasciitis with Concurrent Necrobiotic Granulomatous Dermatitis Related to Checkpoint Inhibition Therapy
by: Adeeb Haroon, et al.
Published: (2022-05-01)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
by: Irena Tan, et al.
Published: (2018-07-01)

Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges
by: Martin Huertas R, et al.
Published: (2019-05-01)

An extremely rare case of nivolumab‐associated macroscopic duodenitis with spontaneous regression
by: Takatora Akizawa, et al.
Published: (2020-07-01)

Nivolumab-Induced Exocrine Pancreatic Insufficiency
by: Boudewijn Sweep, et al.
Published: (2021-11-01)

Nivolumab-associated cutaneous T-cell lymphoma
by: Jennifer A. Marks, MD, et al.
Published: (2021-03-01)

Nivolumab-induced contact dermatitis in a patient with advanced lung cancer
by: Shintaro Sato, et al.
Published: (2020-01-01)

Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma
by: Mathew R. Birnbaum, BS, et al.
Published: (2017-05-01)

Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer
by: Kenji Takada, et al.
Published: (2021-06-01)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019-01-01)

CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab
by: Tomoyuki Matsunaga, et al.
Published: (2022-04-01)

Bilateral corneal perforation in Ipilimumab/Nivolumab - associated peripheral ulcerative keratitis
by: Julia Aschauer, et al.
Published: (2022-12-01)

Nivolumab treatment followed by atezolizumab induced encephalitis and neuropathy with antiganglioside antibodies
by: Shohei Watanabe, et al.
Published: (2021-12-01)

Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
by: Iñigo Les, et al.
Published: (2021-01-01)

Nivolumab induced immune mediated transverse myelitis in a patient with metastatic melanoma: The broad clinical spectrum of immune mediated neurologic disorders
by: Mateo Bover, et al.
Published: (2021-12-01)

Pericardial effusion under nivolumab: case-reports and review of the literature
by: Saade Anastasia, et al.
Published: (2019-10-01)

Successful reintroduction and continuation of nivolumab in a patient with immune checkpoint inhibitor-induced bullous pemphigoid
by: Maria L. Mihailescu, et al.
Published: (2020-12-01)

Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report
by: Takaaki Arigami, et al.
Published: (2020-10-01)

Successful mycophenolate mofetil treatment of a patient with severe steroid‐refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer
by: Ginji Omori, et al.
Published: (2021-02-01)

Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report
by: Jindřich Kopecký, et al.
Published: (2018-09-01)

Role of eosinophilia in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab: Prediction of immune‐related adverse events and favorable outcome
by: Yushi Ueki, et al.
Published: (2023-11-01)

Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities
by: Sadanori Furudate, et al.
Published: (2016-10-01)

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
by: Hiroto Yoneda, et al.
Published: (2021-11-01)

Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
by: Sorane Maezumi, et al.
Published: (2024-08-01)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
by: Bin Zhao, et al.
Published: (2018-10-01)

Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding
by: Emily S. Yin, BS, et al.
Published: (2017-03-01)

Autonomic enteric neuropathy following nivolumab monotherapy in a patient with Lung Cancer
by: Stephanie Andrews, et al.
Published: (2020-12-01)

Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report
by: Anna Carbó-Bagué, et al.
Published: (2021-09-01)

A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy
by: Alice Horisberger, et al.
Published: (2018-12-01)

Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
by: Yasuyuki Miyauchi, et al.
Published: (2021-10-01)

Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review
by: Ammar Haikal, et al.
Published: (2018-01-01)

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
by: Abdulaali R. Almutairi, et al.
Published: (2020-02-01)

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
by: Ken Masuda, et al.
Published: (2019-10-01)

Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response
by: Florence Baettig, et al.
Published: (2019-10-01)

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
by: Valerie Glutsch, et al.
Published: (2019-07-01)

Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report
by: Jacob Appelbaum, et al.
Published: (2018-08-01)

Association between immune-related adverse events and the prognosis of patients with gastric cancer treated with nivolumab: a meta-analysis
by: Ya-Jun Zhang, et al.
Published: (2024-09-01)

Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study
by: Yoshihiko Tasaki, et al.
Published: (2025-01-01)

New risk stratification for adjuvant nivolumab for high‐risk muscle‐invasive urothelial carcinoma
by: Takafumi Saito, et al.
Published: (2024-02-01)

Safety evaluation of fixed‐dose nivolumab in patients with gastric cancer
by: Yusuke Iikura, et al.
Published: (2022-07-01)